Sunshine vitamin: FANCL data reveals Vitamin D is most popular supplement during

ACI expects healthcare antiseptic manufacturers to lose most active ingredients
The US Food and Drug Administration (FDA) will ban some 80% of active ingredients currently allowed for use in healthcare antiseptics, the American Cleaning Institute (ACI) expects.
Plans to require manufacturers to submit data demonstrating the safety and efficacy of their antibacterial ingredients were set out in a 2015 proposed rule - and are expected to become law when the final rule is issued. The FDA will assess data submitted by industry and decide whether to classify actives as "generally recognised as safe and effective" (Gras/Grae), or ban their use in the products.
Triclosana href='https://www.echemi.com/products/pid_Seven3714-triclocarban.html'>Triclocarban.
ACI expects triclosan to face a ban in healthcare products as well, along with more than 20 other ingredients, its associate vice president for environmental safety, Paul DeLeo, told CW+BiocidesHub.
Some substances will be banned due to a lack of support by industry, he said. "Companies know it won't get FDA approval so they are not willing to do the additional testing the agency is requiring."
Others will fail because the data to support them is too challenging to generate. The agency, he says, is asking for "new methods that we are not aware of anyone having successfully completed in this space", but it has been willing to give companies more time.
2026-08-24
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Eastman Tritan Products for FANCL Cosmetics Packaging
-
Japanese brewer Kirin plans to acquire Fancl for $1.4 billion
-
Can Addressing Vitamin D Deficiency, Depression, and Diabetes Reduce the Risk of Young-Onset Dementia?
-
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
-
The battle between Pfizer and Gilead over COVID-19 drugs will continue
-
1200 cases were newly prescribed by Junshi Biologic for mild to moderate disease
-
Twenty-five COVID-19 Vaccines In China Enter Stages Of Clinical Trials
-
Pfizer to Increase Production Capacity of COVID-19 Oral Drugs, Invest 120 Million US Dollars
-
Anke Bio and Afana Collaborate on mRNA Vaccines for Mutant Strains Such as COVID-19 Omicron
-
As Low as $25/session! Pfizer's COVID-19 Oral Drug Paxlovid Generic Drug Price Released
Recommend Reading
-
Private Equity Firm Acquires Lyons Magnus for About $1 Billion as Beverage and Nutrition Ingredients Consolidate
-
LG Chem Enters Semiconductor Stripper Market for the First Time, Cutting Process Time by 50%
-
Global Chemical Giants Light the Fuse: A TDI/MDI Price Storm Sweeps Asia and Europe—Who’s Fueling This “Cost Carnival”?
-
Global Chemical Exports Are Freezing in 2026
-
“Clearing the Floor”: DKSH’s Privatization of Its Malaysian Subsidiary Signals a Silent Power Shift in Asia’s Supply Chain
-
Business Society’s Market Outlook for Soda Ash on August 14, 2026: Volatile but Tending Toward Stronger Consolidation
-
Ethanol Market Prices Continue to Rise
-
Since December, the Chinese phenol market has seen a significant decline
-
Geopolitical Conflicts Drive a Surge in Phthalic Anhydride Prices in China
-
Methanol Market Trading Quiet